NCT07697924 CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome / Endometrial Atrophy / Thin Endometrium)
| NCT ID | NCT07697924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundación IVI |
| Condition | Asherman Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2025-12-18 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 35 participants in total. It began in 2025-12-18 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, platelet-rich plasma (PRP) has emerged as a promising alternative for treating endometrial pathologies that affect the endometrial lining. Several studies have tested this therapeutic approach in human patients, but the results are inconclusive. Moreover, in recent years, different investigations have suggested that PRP derived from umbilical cord blood (hUC-PRP) contains a higher concentration of growth factors and other pro-regenerative molecules than PRP obtained from adult peripheral blood. In our previous pilot study conducted in 15 patients with endometrial atrophy/Asherman syndrome/thin endometrium, preliminary results indicate that hysteroscopic injection of hUC-PRP increases endometrial thickness and improves the endometrial pattern. For this reason, the present study aims to corroborate our previous findings by increasing the number of patients to 35, in prior HRT cycles in these women, to gain a deeper understanding of the effectiveness of this new therapy.
Eligibility Criteria
Inclusion Criteria: * age between 18 and 48 years at the time of recruitment * body mass index (BMI): ≥ 18 kg/m2 and ≤ 35 kg/m2 * endometrial thickness \< 5 mm despite estrogen administration according to each clinic's routine practice for 10 or more days and/or evidence of Asherman syndrome. Exclusion Criteria: * Active genital infection at the time of recruitment * chronic endometritis * known endometrial pathology * psychiatric disorder that could hinder study follow-up * positive results on viral safety testing (HBsAg, HBcAb, HCV, HIV-1, HIV-2, syphilis) * presence of any syndrome or condition that, in the opinion of the principal investigator, could pose a risk to the study or to the patient * any clinically significant abnormality detected during the recruitment process * simultaneous participation in another clinical study that could affect the objectives of the present study, or prior participation in this same study.
Frequently Asked Questions
Who can join the NCT07697924 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 48 Years, studying Asherman Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07697924 currently recruiting?
Yes, NCT07697924 is actively recruiting participants. Visit ClinicalTrials.gov or contact Fundación IVI to inquire about joining.
Where is the NCT07697924 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT07697924 clinical trial?
NCT07697924 is sponsored by Fundación IVI. The trial plans to enroll 35 participants.